4DS Memory (ASX:4DS) - Founder and CEO, Andreas Fouras
Founder and CEO, Andreas Fouras
Source: andreasfouras.com
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • 4DMedical (4DX) signs an agreement with I-MED Radiology Network to begin phase two of its clinical pilot program on its software
  • The pilot program follows the completion of a phase one trial, where patients were referred a 4DMedical XV Lung Ventilation Analysis Software scan, providing detailed scans of lung health   
  • Phase two is set to be complete over the remainder of the year to further assess a potential commercial partnership with I-MED
  • 4DMedical shares are up 0.63 per cent, trading at $1.61 at 2:15 pm AEST

4DMedical (4DX) has signed an agreement with I-MED Radiology Network to begin phase two of its clinical pilot program on its software.

The pilot program follows the completion of a phase one trial, conducted in an I-MED imaging clinic in Victoria where patients were referred a 4DMedical XV Lung Ventilation Analysis Software scan.

4DMedical’s technology can scan a patient’s lung function as they breathe, providing sensitive, early diagnosis, while monitoring changes over time. The software-as-a-service scans are able to deliver complete results, showing subtle lung variations using lower levels of radiation than traditional methods.  

The scans are generated using existing imaging infrastructure, providing doctors with greater insight into the patient’s lung health.

During phase one, the trial analysed lung disorders including asthma, chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis, silicosis and persistent symptoms following COVID-19 infection.  

Having confirmed the compatibility with I-MED’s imaging infrastructure, the clinical pilot will now move into phase two, and will allow radiologists to get to know 4DMedical’s technology.  

“Phase one of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback,” said 4DMedical Founder and CEO, Andreas Fouras.

“Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS contract with I-MED provided that Phase Two is successful.”

Phase two will be completed in a different Australian state over the remainder of the year to further assess a potential commercial partnership with I-MED.

4DMedical shares were up 0.63 per cent, trading at $1.61 at 2:15 pm AEST.

4DX by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece

" HeraMED (ASX:HMD) signs “significant milestone” with a Perth hospital

Digital maternity care company HeraMED (ASX:HMD) has hit a "truly significant milestone" with a Perth hospital,…

" ResApp Health (ASX:RAP) signs LOI to launch diagnostic app in the Philippines

ResApp Health (ASX:RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement…

" Emyria (ASX:EMD) set to begin ultra-pure CBD trial

Emyria (ASX:EMD) is set to begin phase one clinical trials of its ultra-pure CBD drug candidate,…